Market Size of Global Advanced Therapy Medicinal Products (ATMPs) Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 13.00 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Advanced Therapy Medicinal Products Market Analysis
The advanced therapy medicinal products (ATMPs) market is projected to register a CAGR of 13% during the forecast period.
The COVID-19 pandemic has resulted in plummeted revenue generation through approved advanced therapy products designed for non-COVID applications to a manageable extent. This is majorly due to the sudden shift of the global healthcare system toward the management of SARS-CoV-2 infected patients. Nonetheless, the global pandemic has driven the research programs aimed at exploring the application of these therapies in virology research. For instance, in September 2020, ALVR109, an allogeneic T-cell therapy IND application, which is designed for the treatment of patients infected with SARS-CoV-2, received approval from the US Food and Drug Administration (FDA). Similarly, in January 2021, Sorrento Therapeutics Inc. reported positive results from its Phase 1b study of COVI-MSC, a human allogeneic adipose-derived mesenchymal stem cell-based treatment, which is designed for patients suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) or acute respiratory distress (ARD). This broadening application of CAR-T cells in non-oncology applications is certainly expected to benefit the market in terms of revenue growth in the coming years.
Furthermore, a continuous increase in the number of candidates under the global pipeline for advanced therapy is anticipated to bolster the future market revenue. In an analytical article published in Nature Reviews Drug Discovery in June 2021, 2,073 cell therapies in the global pipeline were marked as active, an increase of 572 over the update in 2020 as of April 16, 2021. This is expected to positively impact the market revenue in the coming years.
Moreover, rising competition among the market players to gain substantial market share in the space is anticipated to propel R&D investment flow in the market. For instance, in October 2021, Leucid Bio announced an investment of USD 15.26 million (1 GBP=1.33 USD) for the development of the next generation of innovative CAR-T therapies. Similarly, in June 2021, Blackstone Life Sciences collaborated with Cellex Cell Professionals and Intellia Therapeutics to launch a new CAR-T cell therapy company. These developments are expected to play a vital role in defining market growth.
Advanced Therapy Medicinal Products Industry Segmentation
As per the scope of this report, advanced therapies are novel modes of disease treatment that are based on genes, tissues, or cells. These therapies offer new avenues for disease and injury treatment, thus revolutionizing the pharmaceutical industry. The Advanced Therapy Medicinal Products (ATMPs) market is segmented by Therapy Type (Cell Therapy, Gene Therapy, CAR-T Therapy, Tissue Engineered Product) and Geography (North America, Europe, Asia-Pacific, Rest of the World). The market report also covers the estimated market sizes and trends of 14 countries across major regions globally. The report offers values in USD million for the above segments.
| By Therapy Type | |
| Cell Therapy | |
| Gene Therapy | |
| CAR-T Therapy | |
| Tissue Engineered Product |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| Rest of the World |
Global Advanced Therapy Medicinal Products (ATMPs) Market Size Summary
The Advanced Therapy Medicinal Products (ATMPs) market is poised for significant growth, driven by a robust compound annual growth rate during the forecast period. The COVID-19 pandemic, while initially disrupting revenue streams from non-COVID applications, has spurred research into the use of ATMPs in virology, expanding their application beyond traditional boundaries. This has led to notable advancements, such as the development of therapies targeting SARS-CoV-2, which are expected to contribute to market expansion. The increasing number of candidates in the global pipeline further underscores the market's potential, with a substantial rise in active cell therapies noted in recent analyses. This burgeoning pipeline is anticipated to enhance market revenue, supported by heightened competition among key players investing in research and development to capture market share.
The market's growth is also bolstered by the significant share of tissue-engineered products, attributed to the availability of commercially approved products and their expanding use in medical procedures requiring functional restoration. Strategic initiatives by market players, such as expanding medical coverage policies and investing in innovative CAR-T therapies, are driving segment growth. North America, particularly the United States, is expected to dominate the market due to its strong regulatory framework and funding support. Companies are actively expanding their product portfolios to strengthen market presence, with notable developments like Novartis' launch of a next-generation CAR-T platform. The market remains fragmented, with several key players, including Novartis AG, Gilead Sciences Inc., and Bristol-Myers Squibb Company, leading the charge in this dynamic industry landscape.
Global Advanced Therapy Medicinal Products (ATMPs) Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Number of Clinical Trials for ATMPs
-
1.2.2 Growing Competition Among Market Players
-
-
1.3 Market Restraints
-
1.3.1 Affordability and Financial Sustainability Related Challenges
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Therapy Type
-
2.1.1 Cell Therapy
-
2.1.2 Gene Therapy
-
2.1.3 CAR-T Therapy
-
2.1.4 Tissue Engineered Product
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 United Kingdom
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia-Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Rest of the World
-
-
Global Advanced Therapy Medicinal Products (ATMPs) Market Size FAQs
What is the current Global Advanced Therapy Medicinal Products (ATMPs) Market size?
The Global Advanced Therapy Medicinal Products (ATMPs) Market is projected to register a CAGR of 13% during the forecast period (2024-2029)
Who are the key players in Global Advanced Therapy Medicinal Products (ATMPs) Market?
Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Bluebird Bio, Inc. and Vericel Corporation are the major companies operating in the Global Advanced Therapy Medicinal Products (ATMPs) Market.
